NRx Pharmaceuticals, Inc.
NASDAQ: NRXP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jonathan C. Javitt
- Employees
- 2
- Headquarters
- Wilmington, United States
- IPO year
- 2017
- Market cap
- $61.5M
- Website
- https://www.nrxpharma.com
Loading NRXP…
Loading profile data…Frequently asked questions about NRXP
What does NRx Pharmaceuticals, Inc. (NRXP) do?
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure a...
Where does NRXP trade?
NRx Pharmaceuticals, Inc. (NRXP) trades on the NASDAQ Global Market.
What sector is NRXP in?
NRx Pharmaceuticals, Inc. (NRXP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NRx Pharmaceuticals, Inc.?
Jonathan C. Javitt is the chief executive officer of NRx Pharmaceuticals, Inc. (NRXP).
Where is NRx Pharmaceuticals, Inc. headquartered?
NRx Pharmaceuticals, Inc. is headquartered in United States.
Does NRXP pay a dividend?
NRx Pharmaceuticals, Inc. (NRXP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NRXP go public?
NRx Pharmaceuticals, Inc. (NRXP) completed its initial public offering in 2017.